Document Detail


Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis.
MedLine Citation:
PMID:  15332224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Numerous substances are administered during dialysis for anticoagulation and the treatment of anemia and iron deficiency. The availability of current dialysis membranes is diverse, but assessment of the effects of different membranes on these routinely administered substances is lacking. This prospective study appraises specific effects of 7 dialysis membranes (4 low-flux membranes, 3 high-flux membranes) on the handling of 4 commonly administered agents (epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose) during dialysis.
METHODS: Using a different membrane sequentially, 6 stable hemodialysis patients were treated with epoetin alfa, enoxaparin, and iron sucrose, and 6 patients with darbepoetin alfa. Serum concentrations (predialyzer and postdialyzer) of each substance were assessed after administration and after 4 hours of dialysis (predialyzer).
RESULTS: Overall, use of low-flux membranes resulted in similar serum concentrations for all compounds. However, use of high-flux membranes showed reduced antifactor Xa levels immediately (predialyzer, P = 0.028; postdialyzer, P = 0.027) and 4 hours after (P = 0.001) administration of enoxaparin compared with low-flux membranes. Variable changes in darbepoetin concentrations also were found between the high-flux membranes during dialysis (P = 0.009). Although peak serum concentrations of all compounds were inversely proportional to body weight, the percentage of change during dialysis was not related to dosage or body weight.
CONCLUSION: High-flux membranes may require greater doses of enoxaparin to ensure adequate anticoagulation during dialysis and may be associated with variable changes in darbepoetin concentrations. For other compounds, no noteworthy difference among membranes was defined.
Authors:
Lawrence P McMahon; Kate Chester; Rowan G Walker
Related Documents :
687164 - Inadequate clearance of small molecular weight solutes during hemofiltration using cupr...
10415554 - Control of complement activities for immunoisolation.
10526784 - Membrane-based sample preparation coupled on-line to chromatography or electrophoresis.
9360654 - Restriction coefficients of low molecular weight solutes and macromolecules during peri...
2765484 - Quantitative fluorescence measurement of chloride transport mechanisms in phospholipid ...
17214454 - Sputtering of c(60) fullerenes physisorbed on ar, xe, h(2)o, o(2), and c(8)f(18) matrix...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  44     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-27     Completed Date:  2005-02-23     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  509-16     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Royal Melbourne Hospital, Parkville, Melbourne, Australia. lawrence.mcmahon@mh.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Enoxaparin / administration & dosage,  blood,  pharmacokinetics
Erythropoietin / administration & dosage,  analogs & derivatives*,  blood,  pharmacokinetics
Female
Ferric Compounds / administration & dosage,  blood,  pharmacokinetics
Glucaric Acid
Hematologic Agents / administration & dosage,  blood,  pharmacokinetics*
Humans
Male
Middle Aged
Prospective Studies
Recombinant Proteins
Renal Dialysis / instrumentation*
Chemical
Reg. No./Substance:
0/Enoxaparin; 0/Ferric Compounds; 0/Hematologic Agents; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 113427-24-0/epoetin alfa; 15UQ94PT4P/darbepoetin alfa; 25525-21-7/Glucaric Acid; 8047-67-4/ferric oxide, saccharated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of differing blood lines on delivered blood flow during hemodialysis.
Next Document:  Trends and dynamics of changes in calcification score over the 1-year observation period in patients...